Symptomatic and hemodynamic benefit of pentaerythrityl tetranitrate and hydralazine in a case of congestive heart failure.
Gori
Tommaso
T
2. Medizinische Klinik, Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany. tommaso.gori@ukmainz.de
Münzel
Thomas
T
D000368:Aged; D002311:Cardiomyopathy, Dilated / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D004359:Drug Therapy, Combination; D004417:Dyspnea / Q000188:drug therapy / Q000209:etiology; D006333:Heart Failure / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D006830:Hydralazine / Q000627:therapeutic use*; D008297:Male; D010417:Pentaerythritol Tetranitrate / Q000627:therapeutic use*; D020127:Recovery of Function; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000627:therapeutic use*; D016277:Ventricular Function, Left / Q000187:drug effects*
D014665:Vasodilator Agents; D010417:Pentaerythritol Tetranitrate; D006830:Hydralazine